492 related articles for article (PubMed ID: 26778644)
1. Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
Nishina T; Moriwaki T; Shimada M; Higashijima J; Sakai Y; Masuishi T; Ozeki M; Amagai K; Negoro Y; Indo S; Denda T; Sato M; Yamamoto Y; Nakajima G; Mizuta M; Takahashi I; Hiroshima Y; Ishida H; Maeba T; Hyodo I
Clin Colorectal Cancer; 2016 Sep; 15(3):236-42. PubMed ID: 26778644
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Mizushima T; Tamagawa H; Matsuda C; Murata K; Fukunaga M; Ota H; Hasegawa J; Tsujie M; Fukuzaki T; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Oncology; 2015; 89(3):152-8. PubMed ID: 25967649
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of first-line chemotherapy with uracil-tegafur plus oral leucovorin in elderly (≥75 years) Japanese patients with metastatic colorectal cancer: SGOSG-CR0501 study.
Matsumoto T; Nishina T; Mizuta M; Tsuji A; Watanabe R; Takahashi I; Watanabe Y; Moriwaki T; Maeba T; Hyodo I
Int J Clin Oncol; 2015 Feb; 20(1):111-6. PubMed ID: 24553862
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of uracil-tegafur with leucovorin in elderly (> or = 75 years old) patients with colorectal cancer: ECOG 1299.
Hochster HS; Luo W; Popa EC; Lyman BT; Mulcahy M; Beatty PA; Benson AB
J Clin Oncol; 2007 Dec; 25(34):5397-402. PubMed ID: 18048821
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
Pazdur R; Lassere Y; Rhodes V; Ajani JA; Sugarman SM; Patt YZ; Jones DV; Markowitz AB; Abbruzzese JL; Bready B
J Clin Oncol; 1994 Nov; 12(11):2296-300. PubMed ID: 7964943
[TBL] [Abstract][Full Text] [Related]
9. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
10. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Yamaguchi K; Taniguchi H; Komori A; Narita Y; Nitta S; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K; Mori K; Igarashi Y
BMC Cancer; 2015 Aug; 15():601. PubMed ID: 26311588
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802).
Ohta T; Kato T; Kawakami H; Miyake Y; Goto M; Iwamoto S; Otsuji T; Nakamura M; Sugimoto N; Okamura S; Kotaka M; Tsujie M; Tokunaga Y; Mishima H; Hata T; Shimokawa T; Kurokawa Y; Satoh T
Int J Clin Oncol; 2020 Jul; 25(7):1291-1298. PubMed ID: 32219630
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
Carmichael J; Popiela T; Radstone D; Falk S; Borner M; Oza A; Skovsgaard T; Munier S; Martin C
J Clin Oncol; 2002 Sep; 20(17):3617-27. PubMed ID: 12202662
[TBL] [Abstract][Full Text] [Related]
14. Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study.
Francois E; Smith D; Dahan L; Michel C; Perrier H; Mari V; Seitz JF; Follana P; Evesque L; Chamorey E
J Chemother; 2012 Aug; 24(4):207-11. PubMed ID: 23040684
[TBL] [Abstract][Full Text] [Related]
15. Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Oncopaz Cooperative Group.
Feliu J; González Barón M; Espinosa E; García Girón C; de la Gándara I; Espinosa J; Colmenarejo A; Jalón JI; Fernández Y; de Castro J
Cancer; 1997 May; 79(10):1884-9. PubMed ID: 9149013
[TBL] [Abstract][Full Text] [Related]
16. A combination of oral uracil-tegafur plus leucovorin (UFT + LV) is a safe regimen for adjuvant chemotherapy after hepatectomy in patients with colorectal cancer: safety report of the UFT/LV study.
Saiura A; Yamamoto J; Hasegawa K; Oba M; Takayama T; Miyagawa S; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Makuuchi M; Kokudo N
Drug Discov Ther; 2014 Feb; 8(1):48-56. PubMed ID: 24647158
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.
Nishina T; Kato T; Yamazaki K; Yoshino T; Miyata Y; Esaki T; Moriwaki T; Boku N; Hyodo I
Cancer Chemother Pharmacol; 2015 Sep; 76(3):547-53. PubMed ID: 26198316
[TBL] [Abstract][Full Text] [Related]
18. Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer.
Kusumoto T; Sunami E; Ota M; Yoshida K; Sakamoto Y; Tomita N; Maeda A; Mochizuki I; Okabe M; Kunieda K; Yamauchi J; Itabashi M; Kotake K; Takahashi K; Baba H; Boku N; Aiba K; Ishiguro M; Morita S; Sugihara K
Clin Colorectal Cancer; 2018 Jun; 17(2):e153-e161. PubMed ID: 29249584
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial.
Hasegawa K; Saiura A; Takayama T; Miyagawa S; Yamamoto J; Ijichi M; Teruya M; Yoshimi F; Kawasaki S; Koyama H; Oba M; Takahashi M; Mizunuma N; Matsuyama Y; Watanabe T; Makuuchi M; Kokudo N
PLoS One; 2016; 11(9):e0162400. PubMed ID: 27588959
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14-day schedule.
Pazdur R; Lassere Y; Diaz-Canton E; Bready B; Ho DH
Invest New Drugs; 1997; 15(2):123-8. PubMed ID: 9220291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]